ADMA Biologics Q3 Earnings Call Highlights
ADMA Biologics reported Q3 gross profit of $99.9M, up from $75.6M YoY, with gross margin at 71%. GAAP net income rose 37% YoY to $49.9M. ASCENIV revenue is expected to grow ~25% for the full year, while BIVIGAM faced pricing pressures. The company plans to present real-world outcomes data at an upcoming conference and received constructive FDA feedback on SG-001. ADMA repurchased 16.5M shares and targets $200M in repurchases for 2026.
How this was made
The 30-second read
Why it matters
Earnings beat and strong cash flow support a bullish outlook, but execution risk on the SG‑001 pipeline remains.
Market read
The earnings release provides fresh material for traders; positive surprise may drive short‑term buying, while pipeline uncertainties add risk.
What to watch
Uncertainty around SG‑001 IND timeline and potential regulatory delays may temper upside.
Background
ADMA Biologics reported Q3 results, highlighting growth in its ASCENIV product, margin expansion, and a $181.4M share repurchase program.
Ticker impact
Q3 earnings release shows revenue growth, higher gross margin, profit increase and a $181M share repurchase, all disclosed for the first time.
likely upside as market prices in higher earnings and continued share repurchases
Revenue and profit metrics exceeded prior expectations; margin expansion and a sizable buyback indicate confidence from management and may attract buyers.
Market effects
Positive earnings may lift the broader plasma‑derived biologics sector as ADMA demonstrates demand resilience.
Limited to US biotech investors; no broader regional effect.
Modest, confined to niche biotech space.
Counterpoint
Despite earnings beat, the high days‑sales‑outstanding and pricing pressure on BIVIGAM could weigh on near‑term performance.
Key entities
- companyADMA Biologics
Biopharma focused on plasma‑derived immunoglobulin therapies.
